HOME >> MEDICINE >> NEWS
Physicians not 'easy marks' for drug sales reps, argues O.R. study

Doctors are far more wary of pharmaceutical companies' aggressive marketing than generally believed and don't easily yield to pressure to switch prescriptions, according to a paper being presented at a conference of the Institute for Operations Research and the Management Sciences (INFORMS).

"Are physicians easy marks?" ask Natalie Mizik of Columbia University and Robert Jacobson of the University of Washington in a paper of the same name. "To the contrary, our results show that physicians are "tough sells" in that sales force activity has modest to very small influence on prescribing behavior."

A related study by a second set of researchers suggests that distributing drug samples is less a method to sway physicians than a way of contrasting medications and helping manufacturers maintain market share.

The papers are being presented today at the INFORMS Marketing Science Conference, which takes place at the Robert H. Smith School of Business in the University of Maryland. The conference began on June 13 and concludes on June 15.

Study of Three Drugs

The authors, noting accusations that pharmaceutical sales representatives (PSRs) compromise physician integrity, obtained access to a database that allowed them to assess the impact that interactions with sales reps have on the number of new prescriptions issued by physicians.

The study sample involved three different drugs and 74,075 American physicians. The database contained information for 24 months on the number of new prescriptions issued for a drug by a given physician, the number of 'detailing' sales calls the physician received that month for the drug, and the number of free drug samples that the rep left with a physician. The data was provided on condition of anonymity.

The drugs differ: they come from different therapeutic areas; they have been on the market from less than 1 year to 11 years; and they have achieved different levels of commercial success their annual
'"/>

Contact: Barry List
barry.list@informs.org
410-691-7852
Institute for Operations Research and the Management Sciences
13-Jun-2003


Page: 1 2 3

Related medicine news :

1. Physicians may not be accurate in their confidence levels of their diagnoses, says Pitt study
2. Physicians call for increased funding for federal infectious disease programs
3. Physicians response to religion-related conflicts in medicine
4. Physicians may need to dig deeper when treating HIV-related lymphomas
5. American College of Chest Physicians announces new Critical Care Institute
6. Chronic care medicine: Physicians say help!
7. Physicians have mixed opinions about consumer-targeted pharmaceutical ads
8. Physicians, patients must work together on new electronic relationships
9. Physicians can help family members caring for dying loved ones
10. American College of Chest Physicians to offer developing nations free access to medical journal
11. Physicians and patients rarely discuss costs

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Physicians not easy marks for drug sales reps argues study

(Date:11/27/2014)... November 27, 2014 Now that Thanksgiving ... has officially launched, Emassagechair.com has announced its ... Discount Event. , Negotiating on behalf of their ... massage chair brands, Emassagechair.com has generated significant buzz in ... and biggest discounts yet. , Shoppers are excited for ...
(Date:11/27/2014)... OXNARD, CA (PRWEB) November 27, 2014 ... All-on-4™ dental implants procedure will help one person ... rehabilitation. , Dr. Saj Jivraj and Dr. Mamaly Reshad ... Woodland Hills, Calif., have launched a website devoted to ... A section of the website would be devoted to ...
(Date:11/27/2014)... Washington, DC (PRWEB) November 27, 2014 “Wekho” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review ... follow locations instead of people. , An interesting new way ... for iOS and Android devices. It’s called Wekho and ...
(Date:11/27/2014)... Developers and plugin specialist of Final Cut Pro ... FCPX to the next level. , “ProPip allows users to ... of a mouse,” said Christina Austin, CEO of Pixel Film ... appreciate.” , With ProPip users can show off their ... ProPip is great for commentaries, news casting, and more. PROPIP™ ...
(Date:11/27/2014)... November 27, 2014 This is ... Global Insulin industry. For an overview analysis, the ... application, industry chain structure, industry overview, policy analysis, ... Insulin industry covers information on policy, plans ... cost structure and much more. , ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 2Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 3Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 4Health News:World-Renowned Oxnard All-on-4™ Dental Implants Experts to Give Away Full Mouth Rehabilitation Annually 5Health News:A New Geolocation Mobile Application and was Featured on NewsWatch Television on October 30, 2014 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 2Health News:Insulin Industry Analysis (Supply, Consumption) for China, America, Korea, France & Japan Research Now at ReportsnReports 3
(Date:11/26/2014)... Nov. 25, 2014  Unilife Corporation (NASDAQ: UNIS, ASX: ... delivery systems, today announced that its Chairman and CEO, ... the Piper Jaffray 26th Annual Healthcare Conference at the ... Tuesday, December 2, 2014. The conference ... "live" listen only Webcast. To listen, please go to: ...
(Date:11/26/2014)... and LONDON , Nov. 25, ... AstraZeneca (NYSE: AZN ) today announced that AMAGINE-2 ... doses of brodalumab in more than 1,800 patients with moderate-to-severe ... Stelara ® (ustekinumab) and placebo at week 12. Brodalumab ... analysis group were each shown to be superior to Stelara ...
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
Breaking Medicine Technology:Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2
Cached News: